Targovax has preliminary clinical results showing its cancer vaccine can reduce the size of mesothelioma tumors in the lung.
Targovax, a Norwegian biotech, has Phase I/II clinical results showing its peptide vaccine ONCOS-102 successfully reduced tumor sizes in 3 out of 6 patients after six months. One patient had a partial response. The disease stayed stable in the remaining two patients.
It’s important to note that the cancer vaccine was only tested in six patients, too small to draw conclusions, and the company will now see if the treatment’s effects hold up in a larger cohort of 30 patients.
Targovax’s ONCOS-102 works by injecting an oncolytic virus straight into the tumor, which specifically causes tumor cells to break open and release antigens. The patient’s immune system learns to recognize these antigens and attack other tumor cells.
Amgen’s Imlygic is currently the only oncolytic virus on the market. Targovax’s CMO Magnus Jäderberg believes this could be the start of an interesting trend.
Image by Billion Photos/Shutterstock